ARCHIVES

Pfizer’s Inlyta Gives FDA a Teaching Moment: Not All PFS Advantages Are Created Equal

This article is from The Cancer Letter archive.

Vol. 37 No. 46 | December 16, 2011

Download PDF Visit The Full Archive

Related Articles

AACR to honor eight scientists with lecture awards.

February 13, 2004

ODAC Recommends Approval Of Paxen; Will IVAX Break Into $1 Billion Market

September 26, 1997

Clinical Trials Approved By NCI CTEP During May

June 28, 2002

Guest Editorial: A Near-Term Solution: NCI And COG Agree on Plan to Maintain Enrollment

May 23, 2014

ASCO Annual Meeting Abstracts Posted Online

May 28, 2010

Race For The Cure Grants For National Capital Area.

June 29, 2001